Fireside Chat Speakers, Programming Announced for 2017 BIO Investor Forum

BIO announces programming for the upcoming BIO Investor Conference Oct. 17-18 in San Francisco including Kristina Burow, Managing Director of ARCH Venture Partners and Dr. Richard Scheller, Chief Science Officer & Head of Therapeutics for 23andMe. The annual conference explores global investment trends and opportunities in life sciences. Early and mid-stage private as well as emerging public companies poised for growth in 2018 are the focus of the event.  

BIO Submits Comments Re: Hospital Inpatient Prospective Payment Systems (IPPS) Proposed Rule

BIO submitted comments in response to the Centers for Medicare and Medicaid Services' (CMS's) Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System Proposed Policy Changes and Fiscal  Year 2018 Rates Proposed Rule on June 13, 2017. BIO supports the development and use of appropriate, evidence-based quality measures throughout the healthcare system as a component of improving efficiency and clinical outcomes; additionally, we support policy proposals driven at increasing access to innovative care. BIO's comments in the letter are divided into two sections - the first focusing on the proposals contained in the FY 2018 Proposed Rule, and the second for providing feedback on the Request for Information.

BIO: Senate Passage of FDA User Fee Package Important Victory for Patients, Medical Innovation

Washington, DC (August 3, 2017) – Biotechnology Innovation Organization (BIO) President and CEO James C. Greenwood issued the following statement regarding passage of the Food and Drug Administration Reauthorization Act (FDARA) by the U.S. Senate today:

BIO's 2017 Special 301 Submission

BIO submitted a report to the United States Trade Representative regarding the agency’s 2017 Special 301 Review.

BIO Applauds US Court of Appeals Decision on the Renewable Fuel Standard

The U.S. Court of Appeals for the District of Columbia Circuit today supported BIO's argument that the RFS statute does not allow EPA to rely on demand-side factors under the oil industry’s control as a basis for setting annual renewable fuel volumes.

Biosimilars: BIO Submits Comments on Program for Enhanced Review Transparency and Communication for Original 351(k) Biologics License Applications in Biosimilar User Fee Act II

Re: Docket No. FDA-2017-N-3199: Program for Enhanced Review Transparency and Communication for Original 351(k) Biologics License Applications in Biosimilar User Fee Act II

The 2017 BIO World Congress Comes to a Close in Montreal

The 14th annual BIO World Congress drew 954 attendees. The world’s largest industrial biotechnology event hosted more than 227 speakers in seven education tracks and five plenaries and set a new conference record for partnering meetings.

Democrats' Plan on Drug Costs a “Bad Deal for Patients and the Future of American Innovation”

Plan will restrict seniors’ access to prescription drugs and undermine quest for biopharmaceutical innovations and cures Washington, DC (July 24, 2017) – Biotechnology Innovation Organization (BIO) Director of Communications Brian Newell released the following statement regarding the drug cost plan released today by Congressional Democrats:

Gord Surgeoner to Receive 2017 BIO Leadership and Legacy Award

Dr. Gord Surgeoner, OOnt, former president of Ontario Agri-Food Technologies (OAFT), will receive the 2nd annual BIO Leadership and Legacy Award on Wednesday July 26, 2017, during a lunch plenary session of the 2017 BIO World Congress on Industrial Biotechnology.

BIO Statement on the Status of the U.S.-China 100-Day Plan

Washington, D.C. (July 17, 2017) – The Biotechnology Innovation Organization (BIO) today issued the following statement on the status of the U.S.-China 100-day plan: